WallStSmart

Abbott Laboratories (ABT)vsInfuSystems Holdings Inc (INFU)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 32401% more annual revenue ($46.59B vs $143.34M). ABT leads profitability with a 11.7% profit margin vs 6.0%. INFU appears more attractively valued with a PEG of 1.73. INFU earns a higher WallStSmart Score of 56/100 (C).

ABT

Buy

52

out of 100

Grade: C-

Growth: 4.0Profit: 6.0Value: 3.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

INFU

Buy

56

out of 100

Grade: C

Growth: 6.0Profit: 5.5Value: 5.3Quality: 7.5
Piotroski: 6/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-46.9%)

Margin of Safety

-46.9%

Fair Value

$73.92

Current Price

$110.92

$37.00 premium

UndervaluedFair: $73.92Overvalued
INFUUndervalued (+27.7%)

Margin of Safety

+27.7%

Fair Value

$10.52

Current Price

$12.24

$1.72 discount

UndervaluedFair: $10.52Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$182.49B9/10

Large-cap with strong market position

Free Cash FlowQuality
$2.09B8/10

Generating 2.1B in free cash flow

INFU1 strengths · Avg: 8.0/10
EPS GrowthGrowth
25.0%8/10

Earnings expanding 25.0% YoY

Areas to Watch

ABT3 concerns · Avg: 3.3/10
PEG RatioValuation
2.134/10

Expensive relative to growth rate

P/E RatioValuation
34.1x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-47.5%2/10

Earnings declined 47.5%

INFU4 concerns · Avg: 4.0/10
PEG RatioValuation
1.734/10

Expensive relative to growth rate

P/E RatioValuation
31.2x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Free Cash Flow. Revenue growth of 13.0% demonstrates continued momentum.

Bull Case : INFU

The strongest argument for INFU centers on EPS Growth.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.

Bear Case : INFU

The primary concerns for INFU are PEG Ratio, P/E Ratio, Revenue Growth.

Key Dynamics to Monitor

INFU carries more volatility with a beta of 1.46 — expect wider price swings.

ABT is growing revenue faster at 13.0% — sustainability is the question.

ABT generates stronger free cash flow (2.1B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

INFU scores higher overall (56/100 vs 52/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

InfuSystems Holdings Inc

HEALTHCARE · MEDICAL DEVICES · USA

InfuSystem Holdings, Inc., provides infusion pumps and related products and services in the United States and Canada. The company is headquartered in Rochester Hills, Michigan.

Want to dig deeper into these stocks?